Ocular hypertension (OHT) is a condition characterized by elevated intraocular pressure (IOP) without visible damage to the optic nerve, posing a high risk for developing primary open-angle glaucoma. It affects approximately 3-6 million people in the United States alone. According to the ocular hypertension pipeline analysis by Expert Market Research, the market is witnessing growth due to a rising focus on early diagnosis and targeted ocular therapeutics. Several ocular hypertension drugs are under development, including novel prostaglandin analogs and ROCK inhibitors. With increasing awareness and innovation in ophthalmic drug delivery, the ocular hypertension therapeutics market is expected to expand in the coming years.
Major companies involved in the ocular hypertension pipeline analysis include Santen Pharmaceutical Co., Ltd., Nicox Ophthalmics, Inc., and others.
Leading drugs currently in the pipeline include NCX 470, AGN-193408 SR, and others.
Rising clinical trial activity, expanding therapeutic innovations, and increasing FDA designations are expected to accelerate drug development and commercialization in the coming years for the ocular hypertension drug pipeline.
The Ocular Hypertension Pipeline Analysis Report by Expert Market Research gives comprehensive insights into ocular hypertension therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for ocular hypertension. The ocular hypertension report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The ocular hypertension pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with ocular hypertension treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to ocular hypertension.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Ocular hypertension refers to higher-than-normal intraocular pressure (IOP) without detectable vision loss or optic nerve damage. It occurs when the eye’s aqueous humor does not drain efficiently, causing pressure buildup. This condition increases the risk of developing glaucoma and typically requires regular monitoring to prevent progression.
Ocular hypertension is treated using prostaglandin analogues, beta blockers, alpha agonists, or carbonic anhydrase inhibitors to lower IOP and reduce the risk of optic nerve damage. In December 2024, Gland Pharma received FDA approval for its generic latanoprost 0.005%, a prostaglandin analogue, for treating ocular hypertension, confirming bioequivalence to Pfizer’s Xalatan and planning a 2025 launch.
According to the Cleveland Clinic, an estimated 3-6 million individuals in the United States are affected by ocular hypertension, placing them at elevated risk for glaucoma. According to Mahadi Bashir et al., 2023, glaucoma impacts approximately 70 million people worldwide and is a leading cause of irreversible vision loss. This progressive optic neuropathy highlights the critical need for advancements in ocular hypertension drug development.
This section of the report covers the analysis of ocular hypertension drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The ocular hypertension pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, at 29%, covers a major share of the total ocular hypertension clinical trials. It is followed by phase I at 27%, phase IV at 21%, and phase III at 20%. This well-distributed pipeline indicates strong research and late-stage development, suggesting a promising future for innovation in the ocular hypertension treatment.
The drug molecule categories covered under the ocular hypertension pipeline analysis include small molecule, monoclonal antibody, peptide, polymer, and gene therapy. The ocular hypertension report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for ocular hypertension. Nitric oxide-donating prostaglandin analogues are advancing as a novel drug class in the ocular hypertension pipeline. For instance, NCX 470, developed by Nicox, is a bimatoprost-based eye drop that combines nitric oxide and prostaglandin activity to lower intraocular pressure through dual mechanisms. It recently completed a Phase 3 trial involving 696 patients with open-angle glaucoma or ocular hypertension.
The EMR report for the ocular hypertension pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed ocular hypertension therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in ocular hypertension clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for ocular hypertension. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of ocular hypertension drug candidates.
NCX 470, sponsored by Nicox Ophthalmics, Inc., is undergoing a Phase 3 multi-regional trial to evaluate its safety and efficacy in reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The study is comparing NCX 470 0.1% with latanoprost 0.005%.
AGN-193408 SR, sponsored by AbbVie, is currently undergoing a Phase 1/2 clinical trial to evaluate its safety and efficacy in treating open-angle glaucoma and ocular hypertension. This sustained-release ophthalmic implant targets the prostaglandin F2α receptor to lower intraocular pressure. The study is assessing dose escalation and comparative efficacy across randomized cohorts.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Ocular Hypertension Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for ocular hypertension. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into ocular hypertension collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share